A study carried out by researchers at Brown University has indicated that niclosamide, a drug used to treat tapeworm, and the closely related oxycloxanide, a veterinary parasite drug, could be used to successfully treat strains of the superbug MRSA.
During the study the drugs suppressed the growth of MRSA cultures in laboratory dishes and preserved the life of nematode worms infected with the bacteria. Ninety percent of MRSA-infected worms survived and large zones of growth inhibition in MRSA culture covering the petri dish plate was cleared. Both were also found to be as effective at lower concentrations as vancomycin, the drug currently used as a last resort treatment against the superbug.
Oxyclozanide was discovered to be the more effective of the two in killing the MRSA bacteria. Niclosamide, on the other hand, successfully curbed MRSA growth however it did not completely eradicate it. Moving forward experiments on rodents are now being planned.
Potential issues have been highlighted concerning the rapid way nicolsamide is cleared from the body and the poor job it performs in working its way out of the bloodstream and into tissues. However, it has been suggested that this rapid clearance may not reduce performance and could in fact be an advantage as the toxicity of the drug may be reduced.
With noclosamide already FDA approved and featured on the World Health Organization’s list of essential medicines, there are strong motivations for investigating its use as a boost to the immune system in those that have essay writing uk contracted MRSA. The less toxic oxycozanide could present an even more promising treatment should it be approved for human consumption. As oxycozanide targets the cell membrane rather than metabolic pathways, it could help prevent MRSA developing resistance to the drug.